A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.

Kavanagh, B D; Khandelwal, S R; Schmidt-Ullrich, R K; Roberts, J D; Shaw, E G; Pearlman, A D; Venitz, J; Dusenbery, K E; Abraham, D J; Gerber, M J

Kavanagh, B D; Khandelwal, S R; Schmidt-Ullrich, R K; Roberts, J D; Shaw, E G; Pearlman, A D; Venitz, J; Dusenbery, K E; Abraham, D J; Gerber, M J.

Affiliation

Kavanagh BD; Department of Radiation Oncology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298-0058, USA. bkavanag@hsc.vcu.edu

Int J Radiat Oncol Biol Phys ; 49(4): 1133-9, 2001 Mar 15.

Article de En | MEDLINE | ID: mdl-11240256

Sujet(s)

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links

Collection: 01-internacional Base de données: MEDLINE Sujet principal: Oxygène / Propionates / Radiosensibilisants / Hémoglobine A / Hypoxie cellulaire / Dérivés de l'aniline / Tumeurs Type d'étude: Clinical_trials Limites: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Int J Radiat Oncol Biol Phys Année: 2001 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links